Bright S, Adair J, Secher D
Celltech Limited, Slough, UK.
Immunol Today. 1991 Apr;12(4):130-4. doi: 10.1016/0167-5699(91)90097-D.
Access to a wide range of high quality and increasingly sophisticated reagents and equipment has underpinned the great surge of knowledge in basic immunology and the growing interest in clinical immunointervention. In this article, the first in an occasional series on immunological research and development in industry, Sue Bright and colleagues outline the key steps in a development programme to take a humanized monoclonal antibody into the clinic. The procedures involved in developing such reagents, particularly for clinical use, are long and require considerable ingenuity and scientific creativity.
能够获得种类繁多、质量上乘且日益复杂的试剂和设备,为基础免疫学知识的巨大飞跃以及人们对临床免疫干预兴趣的不断增长奠定了基础。在本文中,这是关于工业界免疫学研发的不定期系列文章中的第一篇,苏·布莱特及其同事概述了将人源化单克隆抗体推向临床的研发计划中的关键步骤。研发此类试剂,尤其是用于临床的试剂,所涉及的程序漫长,需要相当的独创性和科学创造力。